Ritu Baral
Stock Analyst at TD Cowen
(0.68)
# 3,727
Out of 4,825 analysts
36
Total ratings
30%
Success rate
-21.46%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ritu Baral
Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
---|---|---|---|---|---|---|---|
PVLA Palvella Therapeutics | Initiates: Buy | $44 | $24.03 | +83.10% | 1 | Feb 5, 2025 | |
SAGE Sage Therapeutics | Maintains: Hold | $10 → $9 | $7.49 | +20.16% | 6 | Nov 21, 2024 | |
SPRO Spero Therapeutics | Downgrades: Hold | n/a | $0.67 | - | 4 | Nov 18, 2024 | |
ANTX AN2 Therapeutics | Downgrades: Hold | n/a | $1.24 | - | 2 | Nov 18, 2024 | |
RNA Avidity Biosciences | Maintains: Buy | $56 → $78 | $32.69 | +138.61% | 1 | Oct 21, 2024 | |
ALNY Alnylam Pharmaceuticals | Maintains: Buy | $282 → $371 | $255.13 | +45.42% | 4 | Oct 21, 2024 | |
INSM Insmed | Maintains: Buy | $75 → $98 | $72.64 | +34.91% | 3 | Aug 9, 2024 | |
MDGL Madrigal Pharmaceuticals | Maintains: Outperform | $349 → $390 | $327.70 | +19.01% | 1 | Mar 15, 2024 | |
SGMT Sagimet Biosciences | Initiates: Outperform | n/a | $3.93 | - | 1 | Aug 8, 2023 | |
SRPT Sarepta Therapeutics | Maintains: Outperform | $125 → $175 | $62.78 | +178.75% | 1 | Mar 22, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $21 | $14.58 | +44.03% | 1 | Aug 8, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $0.30 | - | 1 | Aug 23, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $10.77 | - | 1 | Jul 20, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.47 | - | 2 | Jul 13, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $23.73 | - | 1 | Jun 8, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $3.57 | - | 1 | Mar 2, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.62 | - | 1 | Jun 29, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.76 | - | 2 | Jul 2, 2018 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $621.10 | - | 2 | Jan 12, 2018 |
Palvella Therapeutics
Feb 5, 2025
Initiates: Buy
Price Target: $44
Current: $24.03
Upside: +83.10%
Sage Therapeutics
Nov 21, 2024
Maintains: Hold
Price Target: $10 → $9
Current: $7.49
Upside: +20.16%
Spero Therapeutics
Nov 18, 2024
Downgrades: Hold
Price Target: n/a
Current: $0.67
Upside: -
AN2 Therapeutics
Nov 18, 2024
Downgrades: Hold
Price Target: n/a
Current: $1.24
Upside: -
Avidity Biosciences
Oct 21, 2024
Maintains: Buy
Price Target: $56 → $78
Current: $32.69
Upside: +138.61%
Alnylam Pharmaceuticals
Oct 21, 2024
Maintains: Buy
Price Target: $282 → $371
Current: $255.13
Upside: +45.42%
Insmed
Aug 9, 2024
Maintains: Buy
Price Target: $75 → $98
Current: $72.64
Upside: +34.91%
Madrigal Pharmaceuticals
Mar 15, 2024
Maintains: Outperform
Price Target: $349 → $390
Current: $327.70
Upside: +19.01%
Sagimet Biosciences
Aug 8, 2023
Initiates: Outperform
Price Target: n/a
Current: $3.93
Upside: -
Sarepta Therapeutics
Mar 22, 2023
Maintains: Outperform
Price Target: $125 → $175
Current: $62.78
Upside: +178.75%
Aug 8, 2022
Maintains: Outperform
Price Target: $32 → $21
Current: $14.58
Upside: +44.03%
Aug 23, 2021
Initiates: Outperform
Price Target: n/a
Current: $0.30
Upside: -
Jul 20, 2021
Initiates: Outperform
Price Target: n/a
Current: $10.77
Upside: -
Jul 13, 2021
Initiates: Outperform
Price Target: n/a
Current: $1.47
Upside: -
Jun 8, 2021
Initiates: Outperform
Price Target: n/a
Current: $23.73
Upside: -
Mar 2, 2021
Initiates: Outperform
Price Target: n/a
Current: $3.57
Upside: -
Jun 29, 2020
Initiates: Outperform
Price Target: n/a
Current: $1.62
Upside: -
Jul 2, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $0.76
Upside: -
Jan 12, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $621.10
Upside: -